|
|
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{drugbox
| |
| | IUPAC_name = (2''R'',3''S'')5-[2-hydroxy-3-(tert-butylamino)-propoxy]<br>tetralin-2,3-diol
| |
| | image = Nadolol_svg.png
| |
| | CAS_number = 42200-33-9
| |
| | ATC_prefix = C07
| |
| | ATC_suffix = AA12
| |
| | PubChem = 39147
| |
| | DrugBank = APRD00301
| |
| | C = 17 |H = 27 |N = 1 |O = 4
| |
| | molecular_weight = 309.401 g/mol
| |
| | bioavailability =
| |
| | protein_bound = 30%
| |
| | metabolism = Nil
| |
| | elimination_half-life = 14-24 hours
| |
| | excretion = [[Kidney|Renal]] and fecal (unchanged)
| |
| | pregnancy_AU =
| |
| | pregnancy_US = C
| |
| | pregnancy_category =
| |
| | legal_AU =
| |
| | legal_UK = POM
| |
| | legal_US = Rx-only
| |
| | legal_status =
| |
| | routes_of_administration = Oral
| |
| }}
| |
|
| |
|
| {{SI}} | | {{Nadolol}} |
| {{CMG}}
| |
|
| |
|
| | {{CMG}}; {{AE}} {{AZ}} |
|
| |
|
| | '''''For patient information, click <u>[[Nadolol (patient information)|here]]'''''</u>. |
| | {{SB}} |
|
| |
|
| ==Overview== | | ==Overview== |
| '''Nadolol''' ('''Corgard''') is a non-selective [[beta-blocker]] used in the treatment of [[hypertension|high blood pressure]], [[Migraine|migraine headaches]], and [[angina pectoris|chest pain]].
| |
|
| |
|
| == Chemistry and pharmacokinetics == | | ==Category== |
| Nadolol is nonpolar and hydrophobic, with low [[lipid]] solubility.
| |
|
| |
|
| == Mechanism of action == | | ==FDA Package Insert== |
| Nadol is a beta-specific sympatholytic which non-selectively blocks beta-1 [[adrenergic receptor]]s which are mainly located in the [[heart]], inhibiting the effects of the [[catecholamine]]s [[epinephrine]] and [[norepinephrine]] and decreasing [[heart rate]] and [[blood pressure]]. It also blocks beta-2 adrenergic receptors which are located in [[bronchial]] [[smooth muscle]], causing [[vasoconstriction]]. By binding beta-2 receptors in the [[juxtaglomerular apparatus]], nadolol inhibits the production of [[renin]], thereby inhibiting [[angiotensin II]] and [[aldosterone]] production. Nadolol therefore inhibits the [[vasoconstriction]] and water retention due to angiotensin II and aldosterone, respectively.
| |
|
| |
|
| The drug impairs [[atrioventricular node|AV node]] conduction and decreases [[sinoatrial node|sinus]] rate.
| | '''| [[Nadolol indications and usage|Indications and Usage]]''' |
| | '''| [[Nadolol dosage and administration|Dosage and Administration]]''' |
| | '''| [[Nadolol dosage forms and strengths|Dosage Forms and Strengths]]''' |
| | '''| [[Nadolol contraindications|Contraindications]]''' |
| | '''| [[Nadolol warnings|Warnings and Precautions]]''' |
| | '''| [[Nadolol adverse reactions|Adverse Reactions]]''' |
| | '''| [[Nadolol drug interactions|Drug Interactions]]''' |
| | '''| [[Nadolol use in specific populations|Use in Specific Populations]]''' |
| | '''| [[Nadolol overdosage|Overdosage]]''' |
| | '''| [[Nadolol description|Description]]''' |
| | '''| [[Nadolol clinical pharmacology|Clinical Pharmacology]]''' |
| | '''| [[Nadolol nonclinical toxicology|Nonclinical Toxicology]]''' |
| | '''| [[Nadolol clinical studies|Clinical Studies]]''' |
| | '''| [[Nadolol how supplied storage and handling|How Supplied/Storage and Handling]]''' |
| | '''| [[Nadolol patient counseling information|Patient Counseling Information]]''' |
| | '''| [[Nadolol labels and packages|Labels and Packages]]''' |
|
| |
|
| Nadolol may also increase [[blood plasma|plasma]] [[triglyceride]]s and decrease [[High density lipoprotein|HDL]]-[[cholesterol]] levels.
| | ==Mechanism of Action== |
| | |
| == Indications == | |
| Nadolol is indicated for treatment of moderate [[hypertension]] and [[angina pectoris|chest pain]]. In patients with severe [[hypertension]], nadolol can also treat [[tachycardia|reflex tachycardia]] due to treatment with vasodilators.
| |
| | |
| == Off-Label Uses==
| |
| A recent study found that, in certain adults with ADHD that had not responded to traditional therapies, or were unable to tolerate them, the addition of nadolol saw increase in attention and focusing capacities, along with a decrease in anxiety, impulsiveness, and somatic discomfort. [[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1940895&dopt=Abstract]]
| |
| | |
| == Contraindications ==
| |
| Patients whose heart rate is largely mediated by the [[sympathetic nervous system]] (e.g. patients with [[congestive heart failure]] or [[myocardial infarction|myocardial infarct]]) should avoid nadolol as it inhibits sympathetic function. Nadolol is also contraindicated in patients with [[bradycardia]] (slow heart rate) because of its vasodilatory effects and tendency to cause bradycardia.
| |
| | |
| Because of its beta-2 activity, nadolol causes pulmonary vasoconstriction and should be avoided in [[asthma]] patients in preference of a [[beta blocker|beta-1 blocker]].
| |
| | |
| As nadolol, like other beta-2 blockers, inhibits the release of [[insulin]] in response to [[hypoglycemia]], it slows patients' recovery from acute hypoglycemic episodes and should be avoided in some patients with [[diabetes mellitus]]. In patients with [[insulin]]-dependent diabetes, a selective beta-1 blocker is preferred over non-selective blockers.
| |
| | |
| == Side effects ==
| |
| * [[Bradycardia]]
| |
| * [[Fatigue (physical)|Fatigue]]
| |
| * [[Bronchospasm]]s
| |
| | |
| ==See also==
| |
| * [[Renin-angiotensin system]]
| |
| * [[Anti-hypertensive]]
| |
| * [[Cardiology]]
| |
| | |
| == External links ==
| |
| * [http://lysine.pharm.utah.edu/netpharm/netpharm_00/druglist/nadolol.htm Nadolol], from the University of Utah School of Medicine
| |
|
| |
|
| ==References== | | ==References== |
| {{note|bioavailability}} {{cite journal | author= Buice RG, Subramanian VS, Duchin KL, Uko-Nne S. | title=Bioequivalence of a highly variable drug: an experience with nadolol. | journal=Pharmaceutical Research | volume=13 | issue=7 | year=1996 | pages=1109-15 }}
| |
|
| |
|
| {{note|ADHD}} | | {{Reflist|2}} |
| {{beta blockers}}
| |
|
| |
|
| [[Category:Beta blockers]]
| |
| [[Category:Drugs]] | | [[Category:Drugs]] |
|
| |
|
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
|
| |
| [[pt:Nadolol]]
| |